Cortexyme is a private biopharma company, developing therapeutics to alter the course of Alzheimers and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration.
Cortexyme was founded based on the seminal discovery by Dr. Stephen Dominy of pathogenic bacteria in the brain of Alzheimers patients. Infection of mice with the same bacteria results in brain infiltration, neurodegeneration and other pathology of Alzheimers. Because the bacteria is persistent and resistant to broad spectrum antibiotics, Cortexyme is now developing small molecules to stop disease progression. Dr. Steve, studied contribution of proteins from the gut that pass through the blood-brain barrier and may affect the neural health of AIDS patients.